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Abstract
Background: Mantle cell lymphoma (MCL) is genetically characterized by the t(11;14)(q13;q32) translocation and a high
number of secondary chromosomal alterations. The contribution of DNA methylation to MCL lymphomagenesis is not well
known. We sought to identify epigenetically silenced genes in these tumours that might have clinical relevance.
Methodology/Principal Findings: To identify potential methylated genes in MCL we initially investigated seven MCL cell
lines treated with epigenetic drugs and gene expression microarray profiling. The methylation status of selected candidate
genes was validated by a quantitative assay and subsequently analyzed in a series of primary MCL (n = 38). After
pharmacological reversion we identified 252 potentially methylated genes. The methylation analysis of a subset of these
genes (n = 25) in the MCL cell lines and normal B lymphocytes confirmed that 80% of them were methylated in the cell lines
but not in normal lymphocytes. The subsequent analysis in primary MCL identified five genes (SOX9, HOXA9, AHR, NR2F2,
and ROBO1) frequently methylated in these tumours. The gene methylation events tended to occur in the same primary
neoplasms and correlated with higher proliferation, increased number of chromosomal abnormalities, and shorter survival
of the patients.
Conclusions: We have identified a set of genes whose methylation degree and gene expression levels correlate with
aggressive clinicopathological features of MCL. Our findings also suggest that a subset of MCL might show a CpG island
methylator phenotype (CIMP) that may influence the behaviour of the tumours.
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Introduction
Mantle cell lymphoma (MCL) is a well-defined lymphoid
neoplasm characterized by a proliferation of mature B lymphocytes
carrying the t(11;14)(q13;q32) translocation that leads to the
overexpression of cyclin D1 [1]. In addition to this initial oncogenic
event, MCL may carry a high number of secondary chromosomal
and molecular alterations that influence the aggressive behaviour of
this tumour [2]. Epigenetic marks, like DNA methylation and
histone modifications, contribute to physiological and pathological
states, including cancer [3]. In tumour cells, aberrant hypermethy-
lation of stretches of CG-rich DNA, called CpG islands, located in
promoter regions might result in inappropriate transcriptional
silencing of tumour suppressor genes (TSG) [4]. Several studies,
including genome-wide screening, have addressed the potential
inactivation of specific TSG by methylation in MCL [5–7].
However, the limited number of cases or genes investigated
in these studies does not allow to adequately determine the
pathogenetic and clinical role of epigenetic gene silencing in this
tumour.
Different genome-wide strategies, including different DNA
microarrays formats and more recently bisulfite based massive
parallel sequencing [8,9], have been developed to identify genes
silenced by CpG hypermethylation in human neoplasias. One of
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the first described approaches involves the pharmacological
reversion of CpG methylation, accomplished by inhibition of
DNA methyltransferase (DNMT) with drugs such as 5-aza-29-
deoxycytidine (5-aza-dC), coupled with the use of gene expression
microarrays to identify methylated silenced genes that would be
reactivated by drug treatment [10]. This reactivation seems to be
reinforced by the concomitant treatment with histone deacetylase
inhibitors (HDACi) like trichostatin A (TSA) [11]. This screening
procedure has shown to be a powerful tool for the identification of
TSG methylated in human cancers [12,13].
In the current study, we sought to identify epigenetically
silenced genes in MCL using an initial genome wide screening
based on pharmacological reversion of CpG methylation and gene
expression microarray analysis in MCL cell lines followed by the
analysis of selected methylated genes in primary MCL and normal
B lymphocytes. This approach has allowed us to identify a set
of genes whose methylation degree and gene expression levels
correlated with aggressive clinicopathologic features of the tu-
mours and the outcome of the patients.
Results
Identification of potentially methylated genes in MCL cell
lines by pharmacological reversion
To identify potentially methylated genes we focused on probe
sets called ‘‘absent’’ in mock-treated cells but called ‘‘present’’ after
5-aza-dC and 5-aza-dC plus TSA. A higher reactivation of these
probe sets was observed with the combination of 5-aza-dC and
TSA (Figure S1). Finally, we selected 618 probe sets that were
induced more than eight times in at least one MCL cell line
compared to mock-treated cells (SignalLogRatio.= 3) (Figure
S2). Twenty nine percent of these probe sets (n = 180) were not
further considered due to poor annotation. Fourteen percent
(n = 88) and 57% percent (n = 350) were mapped to sex and
autosomal chromosomes, respectively (see Figure S2 for a descrip-
tion of the process). The probe sets mapped to sex chromosomes
mainly interrogated cancer/testis antigens (CTAs) (Table S1).
We focused on the probe sets mapped to autosomal chromo-
somes that interrogated a total of 331 genes (Table S2 and Table
S3). A canonical CpG island around the transcription start site was
found in 252 (76%) of these genes (Table S2). We have calculated
that only 53% protein consensus coding sequence (CCDS) genes
interrogated by the HU133plus 2.0 would contain a CpG island
around the transcription start site [14]. This result would confirm
that we obtained a significant enrichment for CpG islands
containing genes (P,1e-10). A pathway analysis identified that
the top molecular and cellular functions represented by our
candidate genes were cell death, cell cycle, and cellular growth and
proliferation.
CpG promoter analysis of candidate genes in cell lines
and primary MCL
To determine the presence of promoter methylation in genes
induced following drug treatment we analyzed 25 candidate genes
containing CpG islands using a MassArray assay. This set was
selected following a bibliography search and included genes de-
scribed as regulated by hypermethylation in human tumours, and
genes whose function might suggest a putative role as TSG. In
total 46 amplicons were designed to interrogate 25 genes in seven
MCL cell lines and in a pooled DNA sample derived from purified
CD19+ B lymphocytes obtained from four different tonsils.
Forty-five of the 46 amplicons were successfully analyzed. The
majority of CpG of all amplicons were unmethylated in normal
DNA, but showed different methylation patterns in MCL cell lines
(Figure 1). A CpG island was considered as methylated when at
least one amplicon showed a median methylation percentage of all
CpG units equal or higher than 65%. Twenty genes out of 25
(80%) showed hypermethylation in at least one MCL cell line,
whereas all of them (CDH1, AHR, CDC14B, CYB1B1, FOXC1,
G0S2, GPX3, HOXA9, LGALS3, MAL, NPTX2, PAX6, PTPRG1,
ROBO1, SOX9, TFPI2, THEM4, TWIST1, and NR2F2) but one
Figure 1. Heat map showing the percentage of methylation for
the 45 amplicons analyzed. Amplicons in red showed a methylation
degree higher than 65%.
doi:10.1371/journal.pone.0019736.g001
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(PEG3) were unmethylated in normal DNA. Only five genes did
not show significant methylation in any of the seven MCL cell lines
(CCND2, HES1, MCAM, RASSF6 and IL17R10) supporting the
good relationship between pharmacological reversion of CpG
methylation and reactivation of gene expression in these MCL cell
lines.
To validate the methylation events identified in the MCL cell
lines we investigated the methylation status of eight genes (CDH1,
AHR, CDC14B, HOXA9, ROBO1, SOX9, NR2F2, and NPTX2) in
38 primary MCL using one of the previously designed amplicons
for each gene (Figure 2A) that showed specific hypermethylation in
at least two MCL cell lines (Figure 1). We included four duplicate
samples to test the reproducibility of the whole approach. The
correlation analysis (r.0.928, P,0.001) and the close clusteriza-
tion of duplicated samples (Figure 2A) confirmed the high
reproducibility of the assay. The unsupervised analysis of the
methylation profile showed two major clusters one of them
contained all the normal samples and a small subset (n = 6) of
primary tumours that appear to have a lower methylation profile
than the rest of MCL (Figure 2A). The study also showed that 7 of
the 8 genes showed different degrees of methylation in primary
tumours.
Gene methylation and clinicopathologic characteristics
of MCL
We analyzed whether the methylation status of single genes
correlated with clinicopathologic parameters of the tumours
(Table 1). A gene was considered to be methylated in primary
MCL when the methylation level detected was at least above 30%
and three times higher than the methylation degree observed in
normal CD19+ lymphocytes. Three genes appeared to be
frequently methylated in primary MCL. SOX9 was found
methylated in 13 out of 38 (35%), HOXA9 in 15 out of 38
(41%), and AHR in 12 out of 38 (32%) samples (Figure 2B). The
other four genes showed methylation in a smaller subset of
patients, NR2F2 in 7 out of 38 (19%), ROBO1 in 5 out of 38 (14%),
NPTX2 in 3 out of 38 (8%), and CDH1 in 3 out of 36 (8%) samples.
CDC14B was not found methylated in primary MCL.
MCL with methylated SOX9 (p = 0.001) or HOXA9 (P= 0.002)
showed significant higher proliferation (Ki-67 index) than
unmethylated tumours (Figure 3 and Table 1). Furthermore, the
number of Ki-67 positive cells correlated significantly with the
methylation levels of SOX9 (rs = 0.497, P= 0.006), HOXA9
(rs = 0.496, P= 0.01), NPTX2 (rs = 0.581, P= 0.001), NR2F2
(rs = 0.460, P= 0.012), and ROBO1 (rs = 0.388, P= 0.038).
In a series of 24 MCL with available CGH data, tumours with
methylated SOX9 (P= 0.023) or HOXA9 (P= 0.006) showed a
higher number of chromosomal abnormalities than unmethylated
cases (Table 1). Concordantly to the above described associations,
the four blastoid cases showed higher degree of methylation of
SOX9 (P= 0.028), HOXA9 (p = 0.05), and ROBO1 (P= 0.037) than
classical MCL.
Survival information was available in 29 primary MCL
(Figure 4). MCL with methylation of SOX9 (P= 0.0019), HOXA9
(P= 0.0023), or AHR (P= 0.0376) had a significantly shorter OS
compared to patients with unmethylated genes (Figure 4).
Although the methylation status of three out of the four remaining
genes (NR2F2, NPTX2, and CDH1) also showed a tendency to be
associated with shorter OS, it did not reach statistical significance.
The methylation status of SOX9, HOXA9, and AHR were
compared with the Ki-67 index in bivariate COX regression
analyses. SOX9 methylation, but not Ki-67, remained as a
significant independent survival predictor (Relative Risk
(RR) = 3.84; P= 0.0086)). When HOXA9 or AHR methylation
were compared with the Ki-67 index, both genes and Ki-67
retained their independent prognostic value (HOXA9, RR = 3.48;
P= 0.0129; Ki-67, RR = 2.9, P= 0.036) (AHR, RR = 3.72;
p = 0.0164; Ki-67 RR = 3.85; P= 0.0075).
CpG methylation profile and clinicopathologic
parameters in MCL
We observed that gene methylation events tended to occur in
the same primary MCL (Figure 5A). To determine whether the
number of methylated genes had an impact on the clinicopath-
ological features of the patients, we classified the tumours into two
groups. One subset included cases with none or only one
methylated gene (n = 24) whereas the second group consisted of
cases with two or more methylated genes (n = 14). MCL that
accumulated methylated genes had higher proliferation
(P= 0.002), increased number of chromosomal abnormalities
(P= 0.006) and the patients had shorter overall survival (OS) than
cases with one or none methylated genes (P= 0.0065) (Figure 3D).
In a multivariate COX regression analysis, both the presence of
methylation in more than one gene and Ki-67 index retained
their predictive value for OS (RR = 3.48, P= 0.0129; RR = 2.9,
P= 0.0036). To further explore the relationship between the
accumulation of methylation events and survival we divided the
cases in three groups corresponding to cases with no methylated
genes (n = 18), cases with methylation of 1 to 3 genes (n = 14), and
cases with more than 3 methylated genes (n = 6). The accumula-
tion of methylated genes was significantly associated with a shorter
OS of the patients (P= 0.007) (Figure 5B).
Gene expression of methylated genes, association with
promoter methylation and survival
To explore the relationship between promoter methylation and
gene expression in primary tumours we performed a qRT-PCR
analysis of SOX9, HOXA9, AHR, ROBO1, and NR2F2 in a series of
36 MCL. We found a modest but statistically significant inverse
correlation between methylation and mRNA levels for SOX9
(rs =20.431, P= 0.02), AHR (rs =20.411, P= 0.027), and NR2F2
(rs =20.387, P= 0.038). The inverse correlation observed for
ROBO1 when all CpG units were considered was not significant.
However, when single CpG units were analyzed, the methylation
of one of the twelve ROBO1 CpG units present in the amplicon
showed a strong inverse correlation with gene expression
(rs =20.575, P= 0.001). Neither global nor single CpG unit
methylation of HOXA9 correlated with gene expression. Normal
lymph node samples showed significant higher expression levels of
SOX9, AHR, NR2F2, HOXA9, and ROBO1 than primary
methylated MCL (Figure S3).
Next, we investigated whether the mRNA expression levels of
the methylated genes would correlate with the OS of the patients.
Patients were divided in low and high groups according to the
median expression of the genes in the tumours. Low mRNA levels
of SOX9 or ROBO1 were associated with a shorter survival of the
patients (P= 0.0015 and P= 0.0485, respectively). Low levels of
NR2F2 and AHR showed a similar tendency but did not reach
statistical significance.
Discussion
In the present study, we have designed a comprehensive strategy
to uncover novel TSG methylated in MCL. The initial phar-
macological unmasking of methylated genes in cell lines was
followed by a validation study in primary tumours, allowing us to
identify a set of genes frequently methylated in MCL. The
methylation and gene expression levels of these genes correlated
Methylated Gene Markers in MCL
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19736
Methylated Gene Markers in MCL
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19736
with aggressive clinicopathological variables of the tumours.
Moreover, our results suggest for the first time that a subset of
MCL might show a CpG island methylator phenotype associated
with higher proliferation, more complex karyotypes and poor
clinical outcome.
The low frequency or absence of methylation in critical TSG
genes commonly inactivated by mutation or deletion in MCL has
challenged the role that DNA methylation might play in MCL
lymphomagenesis [2]. Although several studies have analyzed the
methylation status of few genes in MCL no association with
clinicopathologic features have been described [5,6]. Recently two
groups have reported the use of genome-wide approaches to study
DNA methylation in hematological neoplasms including a small
series of MCL [15,16]. The authors concluded that germinal
center lymphomas display a significantly higher methylation
degree than pre-germinal center tumours such as MCL. However,
the relevance of DNA methylation in MCL remains to be clarified.
The combination of CpG methylation reversion by 5-aza-dC
with microarray analysis has been successfully applied in different
tumour cell lines to identify methylated genes [17,18]. We
performed this approach in a set of seven MCL cell lines, but in
addition to the treatment with 5-aza-dC, we treated the cells with
the combination of 5-aza-dC and TSA. Our initial microarray
data analysis indicates that the previously described synergy
between 5-aza-dC and TSA also seems to occur in MCL cell lines
[11,12]. Our approach is more comprehensive than a previously
published work where the methylation unmasking was performed
in a single MCL cell line using only 5-aza-dC [19].
Our screening performance was supported by two of our initial
results. First, the majority of the selected probe sets mapping to sex
Figure 2. CpG methylation in primary MCL. A) Hierarchical clustering of MCL samples and normal CD19+ B cells. Row methylation values are
represented in a heat map, unmethylation (white) and full methylation (red). Blue colour highlights the cluster containing the four normal samples.
The black arrows indicate the four duplicate DNA samples. B) Values represent the summary of the CpG unit methylation data for each gene. The
samples were clustered using the data standardized for the cut-off used to define gene methylation.
doi:10.1371/journal.pone.0019736.g002
Figure 3. Box plots representing the median and range of the Ki67 index for the groups of primary MCL with methylated (M) and
unmethylated (unM) genes. A) SOX9, B) HOXA9, and C) AHR. D) Proliferation index of MCL subgroups according to the number of concomitant
methylated genes (#1 M: none or only one methylated gene; .1 M: more than one methylated gene).
doi:10.1371/journal.pone.0019736.g003
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chromosomes corresponded to CTAs. These genes are commonly
expressed in testis and/or placenta, but infrequently expressed in
non-germline normal tissues [20], and their expression is
reactivated by 5-aza-dC [21]. The second evidence was that a
significant proportion of the candidate genes located in autoso-
mal chromosomes contained a canonical 59 CpG island (76%),
whereas we estimated that only 53% of CCDS genes interrogated
in the HU133 plus 2.0 microarray would contain one. In addition,
the identification of DNA methylation in a high proportion of the
genes analyzed in MCL cell lines (80%) strongly supports the
effectiveness of our approach. Gene methylation events may occur
during the establishment of cancer cell lines, but in some models
there is a good relationship between the methylation events
detected in cell lines and the methylation pattern of the primary
tumours from which the cell lines were derived [22]. We observed
a good correlation between methylation events in cell lines and
primary MCL since we found partial methylation in 80% of the
genes analyzed in primary MCL. This association suggests that
MCL cell lines are a good model to study epigenetic aspects of
MCL. All these results confirmed that our approach is robust and
reliable, and suggests that we may be able to identify additional
epigenetically regulated genes in the initial set of 252 methylated
candidates. In addition, the pathway analysis showed that the top
molecular and cellular functions overrepresented in our candidate
gene list were cell death, cell cycle and cellular growth and
proliferation. Recently, Leschenko et al. have reported the global
methylation of a series of primary MCL using the HELP assay
[23]. The authors described that the phenomenon of gene
hypomethylation was more frequent than the hypermethylation
in primary MCL. Furthermore, they identified a group of genes
that were hypermethylated in primary MCL compared with naı¨ve
B-cells. Our approach, based in the pharmacological reversion of
DNA methylation, only allow us to identify hypermethylated genes
precluding the evaluation of hypomethylation in our series. When
we compared our list of potentially hypermethylated genes with
the genes described as hypermethylated in MCL by Leschenko we
observed that 28 genes of our study were also described as
methylated in MCL by Leschenko et al.
The five genes that we found methylated in more than 10% of
primary MCL had been reported to be methylated in different
tumour models, but none of them were previously analyzed in
MCL. SOX9 methylation has been described in bladder tumours
and in FL [24,25]. Moreover, SOX9 has shown a tumorigenicity
inhibitor effect in different tumour cells, suggesting a potential
tumour suppressor role [26,27]. Similarly, high levels of AHR
promoter methylation have been described in acute lymphoblastic
leukemia (ALL) and chronic myeloid leukemia (CML) cell lines, as
well as in primary ALL [28]. In solid tumours several evidences
suggest that HOX9A behaves like a TSG. In that sense, HOXA9
hypermethylation has been described in ovarian tumours and in
squamous cell lung carcinomas [29,30]. Interestingly, HOXA9
methylation has also been reported in FL and AML [25,31].
Several evidences, including the detection of ROBO1 methylation
in primary solid tumours and the predisposition of mice carrying
an inactivated ROBO1 allele to generate lymphomas, support the
role of this gene as a classical TSG [32–34]. NR2F2 hypermethy-
lation has recently been described in breast carcinomas and AML
[31,35]. Now, we report a significant association between the
methylation status of these genes and different clinicopathological
features of primary MCL, together with an inversed correlation
between gene expression and methylation levels, suggesting that
this methylation might play a role in the pathogenesis of MCL. In
addition, the determination of DNA methylation in these genes
might be of prognostic value in MCL, but studies in large series of
primary cases are required.
The methylation pattern analysis showed that gene methylation
does not occur stochastically and concordant methylation events
seem to take place in the same primary MCL. The accumulation
of methylated genes was associated with high levels of prolifera-
tion, increased number of chromosomal abnormalities, and lower
OS. This scenario is reminiscent of the condition defined in
epithelial tumours as CpG island methylator phenotype that is
characterized by the accumulation of methylated genes associated
with worse prognosis [36]. Since all samples were selected for the
DNA extraction based on the histological observation of high
tumor cell content, the identification of primary cases without or
with low methylation can not be due to a reduced number of
tumor cells. This phenotype has not only been described in solid
tumours but also in hematological neoplasms such AML and ALL.
Our results would suggest that it might also occur in lymphomas,
and specifically in MCL. Subsequent studies in larger series of
independent cases are required to confirm these findings.
In summary, we have identified new methylated genes in
primary MCL that are associated with several aggressive clinico-
pathological variables. The identification of new methylated genes
associated with the clinical behaviour in MCL patients suggests
that epigenetic changes may play an important role in the
pathogenesis of these tumours and may be the target of new
Table 1. Relationship between gene methylation and clinicopathological features of MCL.
SOX9 HOXA9 AHR No Methylated Genes
unM M unM M unM M #1 .1
Ki-67 (%) n 17 12 17 12 19 10 17 12
mean6sd 16613 46626* 16613 46626* 25623 34627 16613 46626*
CA{ n 13 11 13 11 16 8 13 11
mean6sd 4.562.9 7.863.2* 4.262.6 8.263.0* 5.463.5 7.463.0 4.262.6 8.263.0*
OS{ n 18 11 16 13 19 10 17 12
mean 74.4 29.8 79.4 31.5 69.0 33.8 75.8 32.6
(95% CI)1 49.7–99.2 9.9–49.7* 52.9–106 12.4–50.5* 44.2–93.9 19.5–48.2* 50–102 12–53*
{CA: Number of chromosome alterations,
{OS: Overall survival in months,
195% CI Confidence interval. unM: unmethylated, M: methylated,
*statistically significant at p,0.05.
doi:10.1371/journal.pone.0019736.t001
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therapies. Moreover, we present evidence suggesting that some
MCL cases might display a CpG island methylator phenotype -like
phenotype associated with poor clinical outcome.
Materials and Methods
Cell lines and case selection
Seven well characterized MCL cell lines (UPN1, JEKO1,
HBL2, GRANTA519, MAVER1, NCEB, and Z138) were used
for the initial genome wide screening [37]. Tumour tissue
specimens from 38 MCL patients were obtained from the
Tumour Bank of the Department of Pathology of the Hospital
Clı´nic of Barcelona, and the Institute of Pathology, University of
Wu¨rzburg. The minimum percentage of tumor cells that were
present in the biopsy sections used for DNA extraction were
evaluated following microscopic observation and in all cases
this percentage was higher than 80%. Normal reactive tonsils
from adult healthy individuals were used as a source of normal B-
cells. Briefly, mononuclear fraction was isolated using Ficoll
from the solution obtained by washing the tonsil nodules
with RPMI1640 (BioWhittaker, Cambrex) supplemented with
16.5 mM HEPES (Boehringer Mannheim, Germany). Normal
CD19+ B lymphocytes were obtained by magnetic cell sorting
from four tonsil samples using CD19 human microbeads and
autoMACS separator (MACS, Miltenyi Biotec) following manu-
facturer’s protocol. The characterization of these tumours,
including Ki-67 index and comparative genomic hybridization
(CGH) data had been described previously [38]. The study was
Figure 4. Kaplan-Meier survival curves according to gene methylation status of A) SOX9, B) HOXA9, and C) AHR (M methylated, unM
unmethylated). D) Overall survival (OS) according to the number of concomitant methylated genes (#1 M: none or only one methylated gene;
.1 M: more than one methylated gene).
doi:10.1371/journal.pone.0019736.g004
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approved by institutional review boards at the Hospital Clinic of
Barcelona and the Institute of Pathology of the University of
Wu¨rzburg. Written informed consent was obtained from all
participants and the ethics committees approved this consent
procedure in accordance with the principles of the Declaration of
Helsinki.
Pharmacological reversion of CpG methylation
The pharmacological reversion of the potentially methylated
genes in the cell lines was performed using 5-aza-dC (100 nM
for 72 h, Sigma, Steinheim, Germany) and 5-aza-dC (100 nM for
72 h) followed by incubation with TSA (300 nM the last 24
h, Sigma). Due to the poor chemical stability of 5-aza-dC, fresh
medium containing 5-aza-dC was added every 24 hours. These
drug treatment conditions were established after a prelimi-
nary study of XIST gene expression in MCL cell lines derived
from males by quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) (see Supporting Information S1 and Figure
S4). Mock-treated cells were used as reference. Total RNA was
processed and hybridized onto HG-U133 Plus 2.0 microarrays
following the manufacturer’s recommendations (Affymetrix Inc.,
Santa Clara, Ca). All array data is MIAME compliant and raw
data had been deposited in GEO database (GSE22038).
Promoter methylation analysis
Promoter methylation analysis of twenty five candidate genes
was performed with the MassArrayH EpiTYPERH assay (Seque-
nom, San Diego, CA). Amplicons were designed using the
EpiDesigner application (www.epidesigner.com). Two amplicons
were designed for 19 genes, one amplicon for five genes, and three
amplicons for one gene. The amplicons analyzed are described in
Table S4. Each analyzed amplicon contains several CpGs and the
EpiTyper software indicates the percentage of methylation for
each CpG unit. The degree of methylation of each gene was
defined as the median methylation percentage of the whole set of
CpG units in the amplicons.
Figure 5. Characterization of MCL according to the methylation status of analyzed genes and their respective clinicopathological
features. A) Distribution of the number of methylated genes in primary MCL. The presence of methylation is represented in red and the absence in
green. Clinicopathological variables are represented in a blue-red heat map. B) Kaplan-Meier survival curve of MCL patients according to the
accumulation of methylated genes (Met genes): M0 no methylated genes, M1-3 one to three methylated genes, M.3 more than 3 methylated genes.
doi:10.1371/journal.pone.0019736.g005
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Study of gene expression by qRT-PCR
Total RNA isolation and quality control analysis with the
Bioanalyzer 2100 (Agilent, Palo Alto, CA) were performed as
described before [38]. mRNA expression was analyzed by qRT-
PCR using designed human TaqmanH Gene expression Assays
(Applied Biosystems, Foster City, CA).
Bioinformatic and statistical analysis
The microarray data analysis was performed with different
applications including GeneChip Operating Software (GCOS,
AffymetrixH) and DNA-Chip Analyzer (dChip) (see Supporting
Information S1). An algorithm based on Signal and Detection Call
was applied to select the candidate probe sets. Probe sets that
passed our filter criteria were included independently that other
probe sets of the same gene could be filtered out. The Genome
Browser and Galaxy platforms were used to identify the candidate
genes and the proportion of consensus coding sequence (CCDS)
genes that contain CpG islands around 2 Kb of the transcription
start site and which are interrogated in the HU133plus2.0 array
[39,14]. Pahtway analysis was performed with the Ingenuity
software. The statistical evaluation was performed using nonpara-
metric tests. The means were compared using Mann-Whitney test.
Fisher’s exact test was used for comparison between categorical
data. Overall survival (OS) was estimated using the Kaplan-Meier
method and compared by means of the log-rank test. Cox
proportional-hazards model was used to analyze prognostic
factors. The relationship between two variables was computed
using Pearson correlation (r) and nonparametric Spearman’s rho
correlation (rs). The level of significance was set at 0.05, and all
calculations were performed with the SPSS software package
(version 11; SPSS Inx, IL).
Supporting Information
Table S1 Selected Probes Sets that mapped to sexual
crhomosomes.
(XLS)
Table S2 Candidate genes containing CpG islands
localized to autosomal chromosomes. In bold and
underlined genes validated in MCL cell lines.
(XLS)
Table S3 Non CpG islands genes.
(XLS)
Table S4 Amplicons analyzed in 25 genes indicating the
size of the amplicons (Length) and the number of CpG
locis (CpGs). In bold are indicated the amplicons analyzed in
primary MCL.
(XLS)
Figure S1 A potential synergic effect between 5-aza-dC
and TSA. Reactivation levels of probe sets call absent in mock
treated cells that turn to be called present after both drug
treatments. Red color means higher levels than green color
comparing the gene expression levels in both treatment conditions.
N means number of probe sets.
(TIF)
Figure S2 Flowchart describing the steps followed to
select the final eight genes analyzed in primary MCL.
(TIF)
Figure S3 Box plots representing the median and range
of relative gene expression [A) SOX9; B) AHR; C) NR2F2;
D) ROBO1; E) HOXA9] for the groups of primary MCL
gene methylation status (M: methylated and umM:
unmethylated), and normal lymph nodes (LN).
(TIF)
Figure S4 XIST mRNA expression following 5-aza-dC
titration. a) qRT-PCR of XIST mRNA was performed after 5-
aza-dC titration (30 nM, 60 nM, and 100 nM), and XIST mRNA
levels were compared to mock treated cells. b) Heat Map showing
XIST mRNA levels detected in HBL2 by 6 probe sets after mock,
60 nM 5-aza-dC, 100 nM 5-aza-dC, and 100 nM 5-aza-dC+TSA
treatment. The microarray data (mean of the six probes sets)
comparing drug versus mock treatment is represented in a bar
plot.
(TIF)
Supporting Information S1 Identification of experimental
conditions for pharmacological reversion of gene expres-
sion in MCL cell lines.
(DOC)
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